NCT06279871Phase 3Completed

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

Study sponsor: Arcturus Therapeutics, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-10-09Actual
Enrollment · participants1514Actual
Source updated2025-12-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Actual enrollment increased by 15 participants

Before: 1499 participants (actual). After: 1514 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview